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Introduction {#sec1}
============

Diabetes is increasing in prevalence worldwide, particularly in rapidly developing countries, such as China, which currently has the world\'s largest diabetes epidemic ([@bib42]). Type 1 diabetes (T1D) or type 2 diabetes (T2D) ultimately results in pancreatic β-cell loss and chronic hyperglycemia. The replacement of lost β-cells using various approaches, such as pancreatic or islet transplantation, stem cell differentiation, and mature somatic cell reprogramming, represents a promising therapeutic strategy ([@bib40]). Pancreatic α- and β-cells have similar epigenetic landscapes ([@bib5]), express many of the same transcription factors (e.g., Pax6 and Isl1), and metabolize glucose and secrete hormones via similar mechanisms (e.g., glucokinase and ATP-sensitive K^+^ channel). These similarities make reprogramming α-cells into β-cells easier than other types of cell conversion. α- and β-cells are situated within the islets and are both close to the vasculature ([@bib4]), which suggests that α-cells are well positioned for ideal β-cell function ([@bib35]). Moreover, a small amount of glucagon remaining after α-cell ablation is sufficient to maintain the metabolic effects of glucagon ([@bib35]). Notably, under diverse conditions of β-cell injuries in animals and humans, the α-cell mass is preserved or increased ([@bib26]), which constitutes a potentially abundant source for reprogramming. Thus, endogenous α-cells are an attractive source for β-cell regeneration ([@bib44]). Under certain extreme conditions (e.g., diphtheria toxin-induced β-cell ablation \>99% or combination of pancreatic duct ligation with alloxan), α-cells can spontaneously transdifferentiate into β-cells ([@bib7], [@bib36]). Forced expression of *Pax4* (a master regulator of the β-cell lineage) or selective inhibition of *Arx* (a master regulator of the α-cell lineage) in α-cells can promote α- to β-cell conversion in adult mice of any age ([@bib8], [@bib1], [@bib10]). However, these extreme conditions or transgenic approaches cannot be directly translated into diabetes therapy in humans. Recently, γ-aminobutyric acid and artemisinin (an anti-malarial drug) were identified as chemical inducers of α-to β-cell conversion ([@bib2], [@bib24]). Nevertheless, the effect of small molecules remains to be further clarified ([@bib39]), and the safety of their long-term treatment must be determined in humans. It is highly desirable and valuable to investigate and validate the pro-β-cell neogenic effects of drug candidates that are in both pre-clinical and clinical stages.

In addition to pancreatic β-cells and insulin, the effects of α-cells and glucagon on glucose homeostasis regulation and diabetes development have long been recognized and have become increasingly emphasized ([@bib37]). Blockage of the glucagon receptor (GCGR) by gene knockout, antisense oligonucleotides, or specific antagonists improves hyperglycemia and other metabolic manifestations of insulin deficiency in diabetic subjects ([@bib33], [@bib21], [@bib25]). REMD 2.59, a fully competitive antagonistic human GCGR monoclonal antibody (mAb), and REMD-477, another human GCGR mAb that differs by only one amino acid (which is not involved in glucagon binding) and has an affinity for the GCGR equivalent to that of REMD 2.59, have shown strong hypoglycemic effects in T1D rodents ([@bib43]), T2D rodents, and non-human primates ([@bib45], [@bib28]), as well as patients with T1D ([@bib29]). Notably, blockage of the GCGR in animals resulted in α-cell hyperplasia ([@bib33], [@bib21], [@bib28]). Strikingly, in mice with diphtheria-toxin-induced extreme β-cell loss, *Gcgr* knockout increased glucagon-insulin co-expressing cells ([@bib12]). Moreover, in mice with insulin receptor antagonist-induced severe insulin resistance, GCGR mAb not only expanded the α-cell mass but also increased the β-cell mass ([@bib27]). However, despite these observations, whether the GCGR mAb enlarges the β-cell mass via promoting α- to β-cell conversion in normal and stressed conditions remains to be clarified.

In the present study, we showed that treatment with an antagonistic GCGR mAb induced pancreatic duct-derived α-cell neogenesis, promoted α-cell proliferation, and increased the islet number and area in normoglycemic, streptozotocin (STZ)-induced T1D and non-obesity diabetic (NOD) mice. Moreover, GCGR mAb treatment expanded the β-cell mass likely via α- to β-cell conversion in these two T1D models. Our findings suggest that treatment with the GCGR mAb might be a pre-clinical path for pancreatic β-cell regeneration in diabetes.

Results {#sec2}
=======

GCGR mAb Lowers Blood Glucose and Increases Plasma Glucagon and Active Glucagon-like Peptide-1 Levels in Normal C57BL/6N Mice {#sec2.1}
-----------------------------------------------------------------------------------------------------------------------------

Normal male C57BL/6N mice were treated with REMD 2.59, a human GCGR mAb and competitive antagonist, to evaluate its metabolic effects. During the 4-week treatment, no significant difference was identified between the GCGR mAb and control groups in terms of body weight (p = 0.36) ([Figure 1](#fig1){ref-type="fig"}A). A single injection of the GCGR mAb significantly lowered the fasting and random blood glucose levels (both p \< 0.001). The glycemic levels were lower in the GCGR mAb group than in the control group during the 4 weeks of treatment and were within the normal range with little fluctuation ([Figures 1](#fig1){ref-type="fig"}B and 1C). Weekly administration of the GCGR mAb for 4 weeks significantly increased the plasma glucagon levels compared with those in the control group (131.6 ± 31.0 ng/L vs. 64.7 ± 4.3 ng/L, p = 0.039) ([Figure 1](#fig1){ref-type="fig"}D). Notably, the plasma insulin level was decreased (p = 0.004) ([Figure 1](#fig1){ref-type="fig"}E), whereas active glucagon-like peptide-1 (GLP-1) level was increased (p = 0.019) ([Figure 1](#fig1){ref-type="fig"}F), by the GCGR mAb treatment in the normoglycemic mice.Figure 1Metabolic Parameters in Normal Male C57BL/6N Mice Treated With REMD 2.59, a Human Glucagon Receptor (GCGR) Monoclonal Antibody (mAb), or Saline (as Control) for 4 Weeks(A) Body weight; (B) fasting blood glucose; (C) random blood glucose; (D) plasma glucagon; (E) plasma insulin; (F) plasma active glucagon-like peptide-1 (GLP-1). n = 6--10 mice per group. Data are expressed as the mean ± S.D. Statistical analysis was conducted by Student\'s t test. \*p \< 0.05 (GCGR mAb vs. control); ^\#^p \< 0.05 (posttreatment vs. pretreatment in the same group).

GCGR mAb Induces Pancreatic Duct-Derived α-Cell Neogenesis, Promotes α-Cell Proliferation, and Increases the α-Cell Mass in Normal C57BL/6N Mice {#sec2.2}
------------------------------------------------------------------------------------------------------------------------------------------------

Histological analysis of pancreatic islets was performed using immunofluorescence staining. Treatment with the GCGR mAb induced a massive expansion in the number of glucagon-positive α-cells (48 \[32, 91\] vs. 19 \[8, 36\] per islet slice, p \< 0.001) ([Figures 2](#fig2){ref-type="fig"}A and 2B). Notably, the glucagon-positive α-cells were located not only in the islet mantle zone but also in the islet core, where insulin-positive β-cells are generally detected. The number of insulin-positive β-cells remained unchanged following GCGR mAb treatment (p = 0.42), thereby decreasing the proportion of β-cell numbers to α-cell numbers (p \< 0.001) ([Figures 2](#fig2){ref-type="fig"}A and 2B). Moreover, we also found that the islet number (p \< 0.001) and area (p = 0.001) were significantly increased by GCGR mAb treatment ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C). Interestingly, the insulin labeling intensity, as shown by immunofluorescence staining, was weaker in the GCGR mAb group than in the control group. In contrast to the typical observation that insulin staining is generally located throughout the entire cytoplasm of β-cells, insulin labeling was mainly detected in the cytoplasm around the nucleus and was barely detectable in other parts of the cytoplasm after GCGR mAb treatment ([Figure 2](#fig2){ref-type="fig"}A).Figure 2Histological Analysis in the Pancreata of Normal Male C57BL/6N Mice Treated with the GCGR mAb or Saline Control for 4 Weeks(A) Representative image of an islet immunostained for glucagon and insulin.(B) Quantification of α-cells and β-cells per islet slice and the proportion of β-cell numbers to α-cell numbers. n = 5−8 sections/mouse multiplied by 6--9 mice/group. Data are expressed as the median (interquartile range). Statistical analysis was conducted by the Mann-Whitney test. \*p \< 0.05 (GCGR mAb vs. control).(C) Representative photograph showing glucagon-positive cells located in the ductal region. The ductal lumen is outlined with dashed lines. The arrow indicates glucagon-positive cells in the ductal lining.(D) Representative image of co-labeling for glucagon and cytokeratin 19 (CK19), a marker of mature duct cells. The cells in the small box are enlarged at the top-right corner of the image.Scale bar, 100 μm. See also [Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C, [S2](#mmc1){ref-type="supplementary-material"}A, and [S3](#mmc1){ref-type="supplementary-material"}A.

We subsequently estimated the possible origin of the expanded pancreatic α-cells. We noted that the positioning of these α-cells within the islets was atypical, as most cells were detected in cell clusters close to pancreatic ducts but were not uniformly distributed within the islet mantle zone, as exhibited in the controls. Interestingly, some glucagon-positive α-cells were also detected in the ductal region ([Figure 2](#fig2){ref-type="fig"}C). These findings suggest that these neogenic α-cells might have derived from ducts. We subsequently carried out double-immunostaining using specific antibodies for glucagon and cytokeratin 19 (CK19), a marker of mature duct cells. Again, some glucagon-positive α-cells were located in the duct compartment ([Figure 2](#fig2){ref-type="fig"}D). However, we did not identify the co-localization of glucagon with CK19, which indicates that these neogenic α-cells might not have directly derived from mature duct cells. Moreover, we performed additional double-labeling studies using two other ductal cell markers (Hnf1β and Sox9) to further strengthen our findings of duct- to α-cell neogenesis. Similarly, we found that some glucagon-positive α-cells were located in the duct lining ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Surprisingly, we also found that a few cells were Hnf1β and glucagon double-positive ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We did not find any α-cells located in ducts in the control group. Because Hnf1β and Sox9 are also expressed in the pancreatic progenitors, we inferred that the neogenic α-cells might be differentiated from the progenitors located in ducts. Except for neogenesis, we also performed immunostaining of proliferating cell nuclear antigen (PCNA) to detect cell proliferation. We found that the numbers of glucagon and PCNA double-positive cells were almost doubled by mAb treatment (1.86 ± 0.53% vs. 0.92 ± 0.37%, p = 0.001) ([Figure S3](#mmc1){ref-type="supplementary-material"}A), which suggested neogenic α-cells could also be derived from self-replication.

GCGR mAb Decreases Blood Glucose and Increases Plasma Glucagon, Insulin, and Active GLP-1 Levels in STZ-Induced Diabetic Mice {#sec2.3}
-----------------------------------------------------------------------------------------------------------------------------

To investigate the effects of the GCGR mAb on diabetic mice, we used STZ to establish a T1D model in male C57BL/6N mice. During the 4 weeks of treatment, there was no significant difference in the body weights between the GCGR mAb and control groups in the STZ-induced T1D mice (p = 0.36) ([Figure 3](#fig3){ref-type="fig"}A). A single injection of the GCGR mAb significantly lowered the fasting and random blood glucose levels (both p \< 0.001), and the lowering effects maintained throughout the entire study period ([Figures 3](#fig3){ref-type="fig"}B and 3C). The GCGR mAb treatment significantly increased the plasma glucagon levels, and the increase was more pronounced after the 4-week treatment (1,261.1 ± 290.6 ng/L vs. 80.2 ± 15.1 ng/L, p = 0.005) ([Figure 3](#fig3){ref-type="fig"}D). Notably, the plasma insulin (p = 0.024), C-peptide (p \< 0.001), and active GLP-1 (p = 0.005) levels were substantially higher after treatment with the GCGR mAb ([Figures 3](#fig3){ref-type="fig"}E, 3F, and [S4](#mmc1){ref-type="supplementary-material"}A).Figure 3Metabolic Parameters in Streptozocin (STZ)-Induced Type 1 Diabetic (T1D) Male C57BL/6N Mice Treated with the GCGR mAb or Saline Control for 4 Weeks(A) Body weight; (B) fasting blood glucose; (C) random blood glucose; (D) plasma glucagon; (E) plasma insulin; (F) plasma active GLP-1. n = 6--10 mice per group. Data are expressed as the mean ± S.D. Statistical analysis was conducted by Student\'s t test. \*p \< 0.05 (GCGR mAb vs. Saline); ^\#^p \< 0.05 (posttreatment vs. pretreatment in the same group). The arrowheads in (B and C) indicate the upper detection limit of the glucometer (33.3 mmol/L).See also [Figure S4](#mmc1){ref-type="supplementary-material"}A.

GCGR mAb Induces Pancreatic Duct-Derived α-Cell Neogenesis, Promotes α-Cell Proliferation, and Increases the α-Cell Mass in STZ-Induced Diabetic Mice {#sec2.4}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Histological analysis of the pancreatic islets was carried out using immunofluorescence staining in STZ-induced T1D mice. Similar to the findings in the normal C57BL/6N mice, the GCGR mAb treatment strongly augmented the number of glucagon-positive α-cells (68 \[35, 139\] vs. 53 \[35, 73\] per islet slice, p = 0.035), and the glucagon-positive α-cells were located not only in the islet mantle zone but also in the islet core ([Figures 4](#fig4){ref-type="fig"}A and 4B). Strikingly, the number of insulin-positive β-cells significantly increased (17 \[8, 30\] vs. 5 \[3, 8\] per islet slice, p \< 0.001), and the proportion of β-cell numbers to α-cell numbers substantially increased (0.18 \[0.12, 0.39\] vs. 0.11 \[0.05, 0.16\], p \< 0.001) following GCGR mAb treatment compared with the saline control ([Figures 4](#fig4){ref-type="fig"}A and 4B). Again, the islet number and area per pancreatic section were significantly increased by the GCGR mAb treatment ([Figure S1](#mmc1){ref-type="supplementary-material"}D).Figure 4Histological Analysis in the Pancreata of STZ-Induced T1D Male C57BL/6N Mice Treated with the GCGR mAb or Saline Control for 4 Weeks(A) Representative image of an islet immunostained for glucagon and insulin. The arrows and arrowheads indicate co-labeling, and the co-labeled cells indicated by the arrows are enlarged at the top-right corner of the image.(B) Quantification of α-cells and β-cells per islet slice and the proportion of β-cell numbers to α-cell numbers. n = 6−9 sections/mouse multiplied by 8 mice/group. Data are expressed as the median (interquartile range). Statistical analysis was conducted by the Mann-Whitney test. \*p \< 0.05 (GCGR mAb vs. Saline).(C) Representative photograph showing glucagon-positive cells located in the ductal region. The ductal lumen is outlined with dashed lines. The arrow indicates glucagon-positive cells in the ductal lining.(D) Representative image of co-immunostaining with glucagon and cytokeratin 19 (CK19). The cells in the small box are enlarged at the top-right corner of the image.Scale bar, 100 μm. See also [Figures S1](#mmc1){ref-type="supplementary-material"}D, [S2](#mmc1){ref-type="supplementary-material"}B, and [S3](#mmc1){ref-type="supplementary-material"}B.

We subsequently explored the possible source of the regenerated α-cells. Similar to the findings in the normal C57BL/6N mice, some glucagon-positive α-cells were found in the ductal region ([Figure 4](#fig4){ref-type="fig"}C) in the GCGR mAb-treated diabetic mice, whereas in the saline group not. We inferred that these neogenic α-cells in the GCGR mAb-treated T1D mice might also have originated from ducts. We carried out double immunostaining of glucagon with duct cell markers, including CK19, Sox9, and Hnf1β. Again, some glucagon-positive α-cells were located in the duct compartment ([Figures 4](#fig4){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}B). Although there was no co-localization of glucagon with CK19, some cells were double positive for glucagon with Sox9 or Hnf1β ([Figures 4](#fig4){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}B), which indicates that these neogenic α-cells might not have directly derived from mature duct cells; instead, they may have differentiated from the progenitors located in ducts. Besides, we performed PCNA staining to detect cell proliferation. We found that the numbers of glucagon and PCNA double-positive cells were upregulated by STZ treatment (1.28 ± 0.35% vs. 0.92 ± 0.37%, p = 0.028) and were further boosted by the GCGR mAb treatment (2.76 ± 0.80% vs. 1.28 ± 0.35%, p = 0.002) ([Figure S3](#mmc1){ref-type="supplementary-material"}A), which suggested neogenic α-cells could also be derived from self-replication. Interestingly, we also noted that several PCNA positive cells were located in the duct ([Figure S3](#mmc1){ref-type="supplementary-material"}A), suggesting mAb might promote duct cell or duct progenitor proliferation.

Pancreatic β-Cell Mass Increases and Neogenic β-Cells Are Likely Derived from α-Cell Conversion in GCGR mAb-Treated STZ-Induced Diabetic Mice {#sec2.5}
---------------------------------------------------------------------------------------------------------------------------------------------

The β-cell mass was enlarged in the pancreata of the GCGR mAb-treated T1D mice ([Figures 4](#fig4){ref-type="fig"}A and 4B). To determine the source of the hyperplastic β-cells, further immunofluorescence analyses were performed. The vast majority of the newly formed insulin-positive β-cells were found in the islet core ([Figure 4](#fig4){ref-type="fig"}A), and in some cases, insulin-positive β-cells were located in the islet mantle zone ([Figure 4](#fig4){ref-type="fig"}C), where glucagon-positive α-cells are classically detected. Notably, we did not identify insulin-positive β-cells in the ductal region, which suggests that β-cells might not have directly derived from the duct lining. In some cases, we observed cells co-expressing both glucagon and insulin ([Figure 4](#fig4){ref-type="fig"}A), which indicates that α-cells might have been the origin of β-cells in the GCGR mAb-treated diabetic mice. We also found that some glucagon-positive cells co-immunostained with Pdx1 (a key transcription factor for β-cell maturation and function), Nkx6.1 (another transcription factor for β-cell development and function), or prohormone convertase 1/3 (PC1/3, an important enzyme for proinsulin processing in β-cells) ([Figures 5](#fig5){ref-type="fig"}A--5C).Figure 5Immunofluorescence Analysis of Pancreatic α- to β-Cell Conversion in STZ-Induced T1D Mice Treated with the GCGR mAb(A) Representative photograph of an islet immunolabeled with glucagon and Pdx1, a master transcription factor that participates in pancreatic fate determination and β-cell maturation and function, in STZ-induced T1D C57BL/6N mice treated with the GCGR mAb for 4 weeks.(B) Representative photograph of an islet immunolabeled with glucagon and Nkx6.1, a transcription factor involved in β-cell development and function, in the same animals as (A).(C) Representative photograph of an islet immunolabeled with glucagon and prohormone convertase 1 (PC1/3), an enzyme essential for proinsulin processing in β-cells, in the same animals as (A).(D) Representative image of an islet immunostained with β-gal and insulin in STZ-induced T1D *glucagon-β-gal* mice treated with the GCGR mAb for 8 weeks.The arrows and arrowheads indicate co-labeling, and the co-labeled cells indicated by the arrows are enlarged at the corners of the images. Scale bar, 100 μm. See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

To confirm the α- to β-cell conversion, we used pancreatic α-cell lineage-tracing *glucagon-β-gal* mice. The T1D model in these mice was also induced by STZ, and the mice were treated with GCGR mAb or saline. The body weights, the fasting and random blood glucose levels, the plasma glucagon, insulin and active GLP-1 levels showed similar changes to the non-tracing mice ([Figure S5](#mmc1){ref-type="supplementary-material"}). The immunostaining showed that most of the glucagon-positive cells were labeled with β-gal ([Figure S6](#mmc1){ref-type="supplementary-material"}), suggestive of a high lineage-tracing efficiency. Importantly, we not only observed glucagon and insulin double-positive cells ([Figure S6](#mmc1){ref-type="supplementary-material"}) but also found that some insulin-positive cells contained α-cell labeled β-gal in the pancreata of the GCGR mAb group ([Figures 5](#fig5){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}). These results provided strong evidence that treatment with the GCGR mAb contributed to the conversion of glucagon-expressing α-cells into insulin-positive β-cells in STZ-induced T1D mice.

Next, we detected whether the GCGR mAb treatment promoted β-cell proliferation. We performed PCNA immunostaining and found that the proportion of C-peptide and PCNA double-positive cells was only slightly upregulated by the GCGR mAb in T1D mice (2.17 ± 0.75% vs. 1.37 ± 0.54%, p = 0.08) ([Figure S3](#mmc1){ref-type="supplementary-material"}B), suggesting self-replication may not be a key contributing factor for the increased β-cell mass.

Neogenic β-cells in GCGR mAb-Treated STZ-Induced Diabetic Mice Appear to Be Mature Pancreatic β-Cells {#sec2.6}
-----------------------------------------------------------------------------------------------------

To further characterize the newly formed insulin-positive β-cells in the pancreata of GCGR mAb-treated T1D mice, we performed double immunostaining of insulin with one of several other specific markers for β-cells. Most insulin-positive cells in the islets of the GCGR mAb-treated diabetic mice co-expressed with bona fide β-cell markers, including the transcription factors Pdx1 ([Figure 6](#fig6){ref-type="fig"}A) and Nkx6.1 ([Figure 6](#fig6){ref-type="fig"}B), as well as the proinsulin-processing enzyme PC1/3 ([Figure 6](#fig6){ref-type="fig"}C). These results indicated that the newborn insulin-positive β-cells had the molecular machinery required for functional maturation.Figure 6Immunofluorescence Analysis of β-Cell Markers in the Pancreata of STZ-Induced T1D Mice Treated with the GCGR mAb for 4 Weeks(A) Representative image of an islet immunostained with insulin and Pdx1.(B) Representative photograph of an islet immunolabeled with insulin and Nkx6.1.(C) Representative image of an islet immunostained with insulin and PC1/3.The cells in the boxes are enlarged in the fifth columns. Scale bar, 100 μm.

GCGR mAb Decreases Blood Glucose and Increases Plasma Glucagon and Insulin Levels in Diabetic NOD Mice {#sec2.7}
------------------------------------------------------------------------------------------------------

T1D is characterized not only by the massive loss of β-cells but also an autoimmune insulitis in which autoreactive T-cells are activated. The NOD mouse is a classical tool of autoimmune diabetes. Therefore, we investigated whether GCGR mAb treatment could lower blood glucose, induce α-cell neogenesis, promote α-cell proliferation, and initiate α- to β-cell conversion in diabetic NOD mice. During the 4 weeks of treatment, the body weights in the control group displayed a slight but steady decrease (p = 0.05); in contrast, in the GCGR mAb group, the body weights remained unchanged (p = 0.505). At the end of the treatment, the body weights in the GCGR mAb group were higher than those in the control group (p \< 0.001) ([Figure 7](#fig7){ref-type="fig"}A). A single injection of the GCGR mAb significantly lowered the fasting blood glucose levels (p \< 0.001). The glycemic levels were lower in the GCGR mAb group than in the control group throughout the entire study period (all p \< 0.001, [Figure 7](#fig7){ref-type="fig"}B). Administration of the GCGR mAb significantly increased the plasma glucagon levels compared with the saline control (2,020.5 ± 1,207.6 ng/L vs. 111.0 ± 54.3 ng/L, p = 0.029) ([Figure 7](#fig7){ref-type="fig"}C). Similar to the findings in the STZ-induced T1D mice, the plasma insulin (p = 0.049) and C-peptide (p = 0.023) levels were significantly increased, and the active GLP-1 level was slightly upregulated (p = 0.075) by treatment with the GCGR mAb in the NOD mice ([Figures 7](#fig7){ref-type="fig"}D, [S4](#mmc1){ref-type="supplementary-material"}B, and [S7](#mmc1){ref-type="supplementary-material"}A).Figure 7Metabolic Parameters and Immunofluorescence Analysis in Diabetic Female NOD Mice Treated with the GCGR mAb or Saline Control for 4 Weeks(A--D) (A) Body weight; (B) fasting blood glucose; (C) plasma glucagon; (D) plasma insulin. n = 4--5 mice per group. Data are expressed as the mean ± S.D. Statistical analysis was conducted by Student\'s t test. \*p \< 0.05 (GCGR mAb vs. Saline); ^\#^p \< 0.05 (posttreatment vs. pretreatment in the same group).(E and F) Representative image of an islet immunostained for glucagon and insulin. The arrow and arrowheads indicate co-labeling, and the co-labeled cells indicated by the arrow are enlarged in the bottom-left corner of the image. The infiltrated lymphocytes are outlined with yellow dashed lines, and the ductal lumen is outlined with white dashed lines.(G) Representative photograph showing glucagon-positive cells located in the ductal region in the GCGR mAb-treated NOD mice. The ductal lumen is outlined with white dashed lines. A glucagon-positive cell in the ductal lining was enlarged in the bottom-left corner of the image.Scale bar, 100 μm. See also [Figures S2](#mmc1){ref-type="supplementary-material"}C, [S4](#mmc1){ref-type="supplementary-material"}B, and [S7](#mmc1){ref-type="supplementary-material"}.

GCGR mAb Promotes Pancreatic Duct-Derived α-Cell Neogenesis and Increases the α- and β-Cell Mass in Diabetic NOD Mice {#sec2.8}
---------------------------------------------------------------------------------------------------------------------

Immunofluorescence staining in the pancreata of diabetic NOD mice was performed. We found that, with the exception of the glucagon-positive α-cells and residual insulin-positive β-cells, a large number of infiltrative cells surrounded the islets ([Figure 7](#fig7){ref-type="fig"}E), which was the classical lymphocytic infiltration as previously reported ([@bib6]). Similar to the findings in the normal C57BL/6N and STZ-induced diabetic mice, the GCGR mAb treatment augmented the number of α-cells (29 \[17, 51\] vs. 18 \[11, 26\] per islet slice, p \< 0.001) ([Figures 7](#fig7){ref-type="fig"}E and [S7](#mmc1){ref-type="supplementary-material"}B), and the glucagon-positive α-cells were located not only in the islet mantle zone but also in the islet core ([Figure 7](#fig7){ref-type="fig"}E). The islet structure remained intact, and the number of insulin-positive β-cells was higher in the GCGR mAb treatment group than in the control group in NOD mice (26 \[6, 56\] vs. 4 \[1, 27\] per islet slice, p \< 0.001) ([Figures 7](#fig7){ref-type="fig"}E and [S7](#mmc1){ref-type="supplementary-material"}C). We subsequently explored the cell origin of α-cells. Results showed that α-cell clusters were close to pancreatic ducts ([Figure 7](#fig7){ref-type="fig"}F), and some glucagon-positive cells were located in the ductal region ([Figure 7](#fig7){ref-type="fig"}G) in the GCGR mAb-treated NOD mice, which suggests that these neogenic α-cells might have originated from ducts. We also found glucagon and insulin bihormonal cells ([Figures 7](#fig7){ref-type="fig"}E and 7F), suggestive of α- to β-cell conversion. Notably, most of the bihormonal cells were detected in the neogenic islets. These islets were close to pancreatic ducts and were predominantly composed of α-cells with little or no insulitis ([Figure 7](#fig7){ref-type="fig"}F). These results suggested that the newborn α-cells and bihormonal cells might be resistant to autoimmune reaction.

Discussion {#sec3}
==========

We report an unexpected effect of REMD 2.59, a human GCGR mAb, on inducing the conversion of pancreatic α-cells into β-cells in two T1D mouse models. GCGR mAb treatment seemed to mobilize ductal progenitors to generate α-cells and promote α-cell proliferation, which resulted in increased islet number and area. Pancreatic α-cells were subsequently reprogrammed into β-cells under the diabetic environment. Moreover, the regenerated β-cells expressed markers specific for functional mature β-cells. Therefore, these findings could pave the way for therapies to restore the β-cell mass in diabetic patients.

Long ignored or neglected, pancreatic α-cells, which co-inhabit islets with β-cells, have recently captured attention because of breakthrough findings highlighting the importance of these cells in the maintenance of β-cell functions and glucose homeostasis ([@bib22]). Glucagon, secreted from α-cells, appears to be a major factor in the pathophysiology of diabetes ([@bib20]). Inhibiting glucagon secretion or antagonizing its action is currently considered an innovative approach to diabetes treatment. Several anti-diabetic drugs currently used to treat patients with T2D may partially exert their hypoglycemic effects via reducing glucagon secretion (e.g., GLP-1 receptor agonists, dipeptidyl peptidase-4 inhibitors) or action (e.g., metformin) ([@bib20]). Glucagon exerts its function via its specific receptor, the GCGR. Strategies that specifically target the GCGR, including gene knockout, antisense oligonucleotides, blocking antibodies, and peptide and non-peptide antagonists, have been developed in recent years ([@bib25]). GCGR blockage ameliorates hyperglycemia in animal models of T1D ([@bib9], [@bib43], [@bib12]) and T2D ([@bib33], [@bib45], [@bib28]). Recently, the safety and efficacy of GCGR antagonists were reported in patients with T1D ([@bib29]) and T2D ([@bib19], [@bib17], [@bib18], [@bib3], [@bib38]). However, some antagonists are accompanied by adverse events, such as hypoglycemia, increases in liver enzymes and blood pressure, and disturbed lipid metabolism, in both animal studies and clinical trials ([@bib25]), and small-molecule antagonists (e.g., MK-0893) are particularly associated with these events ([@bib16]). The overall benefit-risk profiles of these antagonists do not support further clinical development ([@bib31]). Therefore, specific inhibition strategy that targets the GCGR without influencing other receptors and with minimal adverse effects is needed for clinical application. REMD 2.59, a human GCGR mAb, displays highly specific and competitive antagonistic activity against the GCGR ([@bib45]), thereby minimizing potential off-target effects. This antibody shows a higher affinity to the GCGR than the cognate ligand ([@bib45]), which enables it to maintain long-lasting efficacy even in hyperglucagonemia. Furthermore, this antibody has a relatively long serum half-life, thereby minimizing dosing regimens. In the present study, weekly administration of the GCGR mAb for 4 or 8 weeks had a significant hypoglycemic effect in normal, STZ-induced T1D and diabetic NOD mice. This result is in line with the data from previous studies in which the same antibody was used ([@bib45], [@bib43]).

Glucagon promotes glucose production mainly via binding with the GCGR to stimulate gluconeogenesis and glycogenolysis ([@bib30]). Therefore, inhibiting the interaction between glucagon and the GCGR can improve glycemic control, primarily by reducing hepatic glucose output via inhibiting glycogenolysis (short term) and gluconeogenesis (long term) ([@bib33], [@bib14], [@bib21]). Another mechanism that may be involved in the hypoglycemic effects is the increased circulating GLP-1 level ([@bib33], [@bib45]). The findings that knocking out the *GLP-1 receptor* or the addition of its specific antagonist exendin (9--39) diminished the hypoglycemic effects of GCGR mAb treatment further support this conclusion ([@bib15]). In the present study, we also found that plasma active GLP-1 was upregulated by GCGR mAb treatment in both normal and T1D mice. Innovatively, we discovered pancreatic α-cell hyperplasia, α- to β-cell conversion and, importantly, elevated plasma insulin levels in GCGR mAb-treated diabetic mice, which may represent another hypoglycemic mechanism that underlies the GCGR blockage.

In our study, treatment with the GCGR mAb boosted the pancreatic α-cell mass in both normal and T1D mice. Similarly, blocking the GCGR by gene knockout, antisense oligonucleotide, or a blocking antibody can promote α-cell neogenesis in normal mice, diet-induced obese mice, and T1D and T2D mice ([@bib33], [@bib21], [@bib28]). Moreover, *GCGR* mutations in human subjects have been associated with α-cell hyperplasia ([@bib32]). However, none of the studies has clarified the ontogeny of GCGR blockage-induced α-cells. We hypothesized that the expanded α-cells derived from pancreatic progenitor differentiation or pre-existing α-cell replication. In pancreatic development and organogenesis, different types of pancreatic cells bud from ducts ([@bib13]). Furthermore, the ducts are often recognized as the progenitor habitation and contribute to the regeneration of endocrine and acinar cells following pancreatic damage in adults ([@bib11]). For this reason, the location of the newly formed cells in the ducts is an indicator of cell derivation from pancreatic progenitors. In our study, most of the expanded α-cells were found in cell clusters close to ducts, some glucagon-positive α-cells were located in the ductal region, and several glucagon-positive cells were Sox9 or Hnf1β positive. These results suggest that the neogenic α-cells induced by the GCGR mAb treatment originated from the progenitor located in ducts. Besides, by cell proliferation detection, we also found that the increased α-cell mass could also result from pre-existing α-cell replication.

In addition to α-cell regeneration, the β-cell mass was boosted in the GCGR mAb-treated T1D mice. Similarly, in severe insulin-resistant mice, normalization of blood glucose with a GCGR antibody expanded the α-cell mass 5.7-fold and unexpectedly doubled the β-cell mass ([@bib27]). These data together with our findings suggest that the GCGR antibody may promote β-cell regeneration under certain conditions. However, the specific factor that initiates this process and how the exact newborn course evolves are largely unknown. Recently, several studies have shown that pancreatic α-cells can be transdifferentiated into β-cells *in vivo* by genetic manipulation, small molecules, and currently available drugs ([@bib8], [@bib7], [@bib36], [@bib1], [@bib10], [@bib2], [@bib24]). Based on these observations, we suspected that the newly formed β-cells induced by the GCGR mAb treatment might also have derived from α-cells. In the GCGR mAb-treated diabetic mice, we observed cells that co-expressed glucagon with insulin or other β-cell-specific markers (including Pdx1, Nkx6.1, and PC1/3), indicative of α- to β-cell conversion. Another group also found an increase in the number of a rare population of cells that co-expressed glucagon and insulin in the islets of both wild-type and *db/db* mice treated with GCGR antibody ([@bib34]). Glucagon and insulin double-positive cells might be the islet progenitor cells or the intermediary status of α- to β-cell conversion or β- to α-cell conversion. To confirm the origin of increased β-cells, we used α-cell lineage-tracing *glucagon-β-gal* mice to verify that α-cells could give birth to β-cells. As previously discussed, we noted the possibility that pancreatic progenitors located in the ductal compartment gave rise to α-cells. Therefore, we investigated whether these neogenic β-cells could also directly derive from the progenitors. However, we did not identify insulin-positive cells in the ductal region after GCGR mAb treatment, which suggests that the progenitor cells might not directly differentiate into β-cells. In addition to derivation from α-cell reprogramming or pancreatic progenitor differentiation, the β-cell mass may increase via self-replication, but we only found a slight increase by the mAb treatment. Taken together, our results showed that treatment with the GCGR mAb promoted β-cell regeneration and the newly formed β-cells at least partially derived from α-cell conversion. Considering the importance and urgency of developing strategies with potential clinical use for diabetes therapy, the stimulating effect of GCGR mAb treatment on the β-cell mass in diabetic subjects may be a potential path for β-cell regeneration. Notably, removal of the GCGR mAb after β-cell mass increasing is a critical indicator to confirm that the β-cell mass is actually functional. Although we found that the β-cell mass in the GCGR mAb-treated diabetic mice increased after the treatment, they are far smaller than that in the normoglycemic mice. We inferred that longer duration of treatment might be needed for the mice treated with the GCGR mAb to get a significant recovery of β-cell mass.

Interestingly, we observed that the insulin staining intensity in pancreatic β-cells was weaker, and the plasma insulin level was decreased in normal C57BL/6N mice after GCGR mAb treatment. These observations could be explained by the fact that blocking GCGR signaling exerted a hypoglycemic effect; therefore, insulin production from β-cells might not be needed as much to maintain glucose homeostasis in normoglycemic mice. This finding may indicate a strategy of pancreatic β-cell rest to preserve β-cell function, similar to β-cell rest for functional recovery after intensive insulin therapy in patients with newly diagnosed T2D ([@bib41]). Thus, treatment with the GCGR mAb might preserve β-cell function in normoglycemic mice with an ample number of β-cells and promote β-cell regeneration in T1D mice with insufficient residual β-cells, thus having different protective effects on β-cells.

As previously discussed, the GCGR mAb treatment induced α-cell hyperplasia and β-cell regeneration in T1D mice. However, the potential mechanism that underlies these results is obscure. Both glucagon and GLP-1 derive from alternative splicing of the common precursor proglucagon by PC2 and PC1/3, respectively. In mature α-cells, PC2 is the main convertase for proglucagon processing and the expression level of PC1/3 is marginal at best. In our study, GCGR mAb treatment induced PC1/3 expression in some pancreatic α-cells, thereby releasing active GLP-1 from these α-cells. This release may account for the upregulation of plasma active GLP-1 levels and the improvement of glucose homeostasis. Similarly, a previous study showed that the pancreatic preproglucagon mRNA level and pancreatic active GLP-1 content were upregulated in GCGR mAb-treated mice, and GCGR mAb-mediated improvements in glycemic control depended on functional GLP-1 receptors in pancreatic islets ([@bib15]). Thus, we speculate that active GLP-1 secreted from α-cells may exert its function on adjacent pancreatic cells in a paracrine manner to promote α-cell expansion and α- to β-cell conversion. A recent study ([@bib23]) reported that GLP-1 increased β-cell regeneration by promoting α- to β-cell transdifferentiation. However, adenovirus (rAd-*GLP-1*), with the risk of viral integration into the genome and carcinogenesis, was used in the study. Our study showed that GCGR mAb, a clinical potential anti-diabetic drug, had the ability to upregulate the circulating and islet local GLP-1 levels and transdifferentiate α-cells into β-cells. Considering the rapid degradation of GLP-1 by the ubiquitous dipeptidyl peptidase-4, the upregulated GLP-1 level in the islet microenvironment might play more important roles than the circulating GLP-1 in the regulation of islet cell phenotype conversion. To test this hypothesis, specific blockage of the pancreatic GLP-1 receptor will be required.

In summary, our study indicated the following: First, treatment with REMD 2.59, a human GCGR mAb, lowered the blood glucose and increased the plasma active GLP-1 levels in normal and T1D mice. Second, GCGR mAb treatment expanded the α-cell mass in normal and T1D mice and increased the β-cell mass in T1D mice. Third, the regenerated α-cells exhibited a ductal ontogeny and self-replication. Fourth, pancreatic α-cells could be converted into β-cells in GCGR mAb-treated T1D mice. Fifth, the newly formed β-cells expressed bona fide β-cell markers, suggestive of functional maturation. Our results suggest that GCGR mAb treatment may represent a promising pre-clinical strategy to improve glycemic control and restore the β-cell mass in diabetic patients.

Limitations of the Study {#sec3.1}
------------------------

First, based on the location of neogenic glucagon-positive cells and the expression of the specific markers of the pancreatic progenitors detected by the immunostaining experiment, we inferred that part of the α-cells derived from the progenitor located in ducts. However, conditioned labeling for pancreatic progenitor cell activation to trace their fate is required to define the exact ductal origin of newly formed α-cells. In fact, several lineage-tracing studies have proved that α-cells can be generated from the duct lining in adult mice ([@bib1], [@bib10]). Second, we verified that α-cells could give birth to β-cells by using *glucagon-β-gal* mice (a constitutive α-cell lineage-tracing model). However, an inducible α-cell lineage-tracing model is a more convincing tool. Third, we found the β-cell mass was enlarged by the GCGR mAb treatment. To confirm the β-cell mass is actually functional, removal of GCGR mAb after the mass increased needs be done. Forth, the potential mechanism of islet cell regeneration induced by the GCGR mAb is obscure. For instance, specific blockage of the pancreatic GLP-1 receptor will be required to determine the effects of GLP-1 in islet microenvironment. Other mechanisms including transcription factors and cytokines also needed to be investigated. Fifth, we only found islet regeneration induced by the antibody in mice and did not perform any experiments in human. Maybe human has different responses to the antibody.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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